RecruitingNot ApplicableNCT06025123

Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2

Prehospital Resuscitation Intranasal Cooling Effectiveness Survival Study 2 (PRINCESS2)


Sponsor

Karolinska Institutet

Enrollment

1,022 participants

Start Date

Mar 27, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this clinical trial is to study the impact of ultra-early transnasal evaporative cooling after cardiac arrest and subsequent hypothermia at hospital, on survival with complete neurologic recovery, compared to currently recommended normothermia. The study population will consist of patients 18-79 years old, with out-of-hospital cardiac arrest with initial shockable rhythm. The main research question it aims to answer is whether there is a difference in survival with complete neurologic recovery at 90 days after cardiac arrest between the group of patients that received ultra-early cooling, compared to the group that was treated with normothermia. Participants will be randomized to two groups. One group (the intervention group) will receive ultra-early trans-nasal evaporative cooling initiated by EMS personnel at the scene of the cardiac arrest, and subsequent systemic hypothermia for 24 hours at hospital arrival. The other group (the control group), will receive standard of care (advanced cardiac life support and normal body temperature (normothermia)).


Eligibility

Min Age: 18 YearsMax Age: 79 Years

Inclusion Criteria3

  • Adult out-of-hospital cardiac arrest patients with initial shockable rhythm
  • Unconsciousness defined as Glasgow Coma Scale < 8
  • Inclusion within 20 minutes from EMS arrival

Exclusion Criteria8

  • Patients are not eligible if they meet one or more of the following criteria:
  • Age ≥ 80 years
  • Obvious non-cardiac causes to cardiac arrest
  • Obvious already hypothermic
  • Obvious barrier to placing intra nasal catheters
  • Have a known Do Not Attempt to Resuscitate (DNAR) order or other limitations in care
  • Have a known terminal disease
  • Known or clinically apparent pregnancy

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEEarly transnasal evaporative cooling with the RhinoChill device

Early prehospital transnasal evaporative cooling followed by systemic hypothermia to 33 degrees Celsius for 24 hours and fever control for 72 hours


Locations(11)

University Hospital Vienna

Vienna, Austria

CHU Saint-Pierre

Brussels, Belgium

Erasme University Hospital

Brussels, Belgium

Europe Hospitals St Elizabeth

Brussels, Belgium

University Hospital Freiburg

Freiburg im Breisgau, Germany

Department of Anesthesiology, Intensive Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Italy

Ljubljana University Medical Centre

Ljubljana, Slovenia

Hospital Universitario La Paz

Madrid, Spain

San Carlos Clinical Hospital

Madrid, Spain

Karolinska University Hospital

Stockholm, Sweden

Södersjukhuset

Stockholm, Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06025123


Related Trials